


Declaration of Interests Register

Technology Appraisal Committee A

Topic: TA572 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes [ID1158]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Stephen Bain	Clinical Expert	Direct financial	Received payment from MSD for consultancy work.		January 2019	N/A	Declare and participate. Not involved in decision making. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Dr John Wilding	Clinical Expert	Direct financial	Received fees for lectures and consultancy work for comparator companies: AstraZeneca, Boehringer, Novo Nordisk, Lilly, Sanofi and Takeda.		January 2019		Declare and participate. Not involved in decision making. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Professor John McMurray	Advisory Committee Member	Direct financial	Principal/co-principal investigator for two international trials, testing the efficacy and safety of dapagliflozin (AstraZeneca) in heart failure and another using bexagliflozin (Theracos) in patients with type 2 diabetes and cardiovascular disease or cardiovascular risk		December 2018	Ongoing	He observed the public part of the meeting and remained absent for the rest of the meeting including decision making. Agreed by: Dr Jane Adam, Chair

Publication Date: 27/03/2019



			factors. He is also one of a group of lead investigators for local trials using empagliflozin (Boehringer Ingelheim) in patients with type 2 diabetes and heart failure.			Janet Robertson, Associate Director
Dr Paul Robinson	Advisory Committee Member	Direct financial	He is employed by and is a shareholder of the manufacturer of the technology.	December 2018	Ongoing	He observed the public part of the meeting and remained absent for the rest of the meeting including decision making. Agreed by: Dr Jane Adam, Chair Janet Robertson, Associate Director
Adrian Griffin	Advisory Committee Member	Direct financial	Employed by Johnson & Johnson who own a comparator treatment in this appraisal.	December 2018	Ongoing	Excluded from meeting.

Link to Committee A interests register : https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.